

Osteoporosis Therapeutics in Asia-Pacific Market 2016 Disease, Clinical Trial, Analysis and Forecasts to 2022

Osteoporosis Therapeutics in Asia-Pacific Market Share, Supply, Disease and Clinical Trial Forecast to 2022

PUNE, INDIA, August 16, 2016 /EINPresswire.com/ -- Wiseguyreports (WGR) Announces the Publication of its Research Report – [Osteoporosis Therapeutics](#) in Asia-Pacific Markets to 2022

Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies

Summary

Osteoporosis, the most common metabolic bone disease, is characterized by low bone mass, micro architectural deterioration of bone tissue, and a consequent increase in fracture risk. Osteoporosis is generally known as an asymptomatic disease, as there are no visible signs until a fracture occur. In most of the cases, fracture is the clinical outcome associated with osteoporosis, and it has a complex pathogenesis that involves trauma to the bone and increased skeletal fragility. Osteoporosis is a major global public health problem, associated with significant morbidity, mortality, and socioeconomic burden. An aging global population will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth.

The osteoporosis market is undergoing a gradual transition from a focus on antiresorptive therapies to anabolic drug treatment. The market is set to be driven by recently launched products, and the approval of drugs that will supplement current market leaders and offer greater therapeutic options. The marketed products landscape comprises a wide range of treatment options, including bisphosphonates, SERMs, RANKL inhibitors, a dual-action non-bisphosphonate (strontium ranelate), calcitonins and PTH analogues. Nevertheless, significant unmet need remains for products that can improve bone formation, as well as effective antiresorptive therapies that offer increased compliance with few side effects.

Scope

The osteoporosis Asia-Pacific market will be valued at \$7.7 billion in 2022, growing from \$4.5 billion in 2015 at a CAGR of 7.8%.

- Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the osteoporosis market?

- How will immunotherapies such as Prolia contribute to growth?

- What effect will the patent expirations of currently branded therapies have on market value? The pipeline contains a range of molecule types and molecular targets, including those that are well established in osteoporosis, and novel, first-in-class therapies.

- Which molecular targets appear most frequently in the pipeline?

- Is there strong potential for the pipeline to address unmet needs within the osteoporosis market?

- Will the pipeline address unmet needs related to limited anabolic therapies for osteoporosis

patients?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of novel therapies.

- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?

- How could changes in risk factors such as aging population, calcium and vitamin D deficiency influence the market?

Various drivers and barriers will influence the market over the forecast period.

- What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?

- Which factors are most likely to drive the market in these countries?

CHECK DISCOUNT @ 10% Discount available on Single User

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

- Visualize the composition of the osteoporosis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.

- Analyze the osteoporosis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, - and how they will compete with other therapies.

- Predict osteoporosis market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.

- Identify commercial opportunities in the osteoporosis deals landscape by analyzing trends in licensing and co-development deals.

Learn from Sample Report @ <https://www.wiseguyreports.com/sample-request/598296-osteoporosis-therapeutics-in-asia-of-anabolic-therapies> □

Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 10

2.1 Disease Introduction 11

2.2 Epidemiology 11

2.3 Symptoms 12

2.4 Etiology and Pathophysiology 14

2.4.1 Pathophysiology 14

2.5 Diagnosis 15

2.6 Disease Stages 17

2.7 Prognosis 20

2.8 Treatment Options 21

2.8.1 Treatment Algorithm 21

2.8.2 Pharmacological Treatments 22

2.8.3 Non-Pharmacological Treatments 24

2.8.4 Exercise 24

2.8.5 Dietary Interventions 24

3 Marketed Products 26

- 3.1 Overview 26
- 3.2 Bisphosphonates 26
 - 3.2.1 Risedronate - Warner Chilcott 26
 - 3.2.2 Alendronate - Merck & Co 28
 - 3.2.3 Boniva (ibandronate) - Roche 29
 - 3.2.4 Zoledronic Acid - Novartis 30
 - 3.2.5 Recalbon/Bonoteo (minodronate) - Ono and Astellas Pharma 31
 - 3.2.6 Etidronate - Procter & Gamble and Sumitomo Pharmaceuticals 32
- 3.3 Dual-Acting Non-Bisphosphonates 33
 - 3.3.1 Strontium Ranelate - Servier 33
- 3.4 Selective Estrogen Receptor Modulators 34
 - 3.4.1 Evista (raloxifene) - Eli Lilly 34
 - 3.4.2 Viviant (bazedoxifene) - Ligand and Pfizer 35
- 3.5 Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Inhibitor 36
 - 3.5.1 Prolia (denosumab) - Amgen 36
- 3.6 Calcitonins 37
 - 3.6.1 Calcitonin-salmon 37
- 3.7 Parathyroid Hormone 38
 - 3.7.1 Forteo (teriparatide) - Eli Lilly 38
- 3.8 Comparative Efficacy and Safety of Marketed Products 39
- 4 Pipeline Analysis 42
 - 4.1 Overview 42
 - 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 43
 - 4.3 Pipeline by Molecular Target 45
 - 4.4 Promising Pipeline Candidates 48
 - 4.4.1 Romosozumab (AMG-785) - Amgen 48
 - 4.4.2 Abaloparatide-SC (BA-058-SC) - Radius Health 51
 - 4.4.3 Odanacatib (MK-0822) - Merck & Co 54
 - 4.4.4 Uni-PTH - Uni-Bio Science 56
 - 4.5 Comparative Efficacy and Safety of Pipeline Products 58
 - 4.6 Product Competitiveness Framework 59

...CONTINUED

BUY THIS REPORT @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=598296

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.